 1. Patients will have a diagnosis of CLL or SLL, refractory to or relapsed after at least one prior standard therapy or untreated with del17p by fluorescence in-situ hybridization FISH high-risk cytogenetics and have an indication for treatment by IWCLL 2008 criteria Cohort 1 OR have been on ibrutinib for at least 9 months with measurable persistent disease absolute lymphocyte count ALC 4KmuL, any lymph node 1.5 cm by CT scan, or 30 lymphocytes on bone marrow aspirate differential Cohort 2, OR patients will have a diagnosis of RT, refractory to andor relapsed after at least one prior standard therapy or untreated with del17p by FISH high-risk cytogenetics Cohort 3. 